Loading organizations...
Epimede is a Belgian private equity fund investing in high-growth, non-listed technological SMEs. The firm targets promising early-stage companies, deploying capital primarily to accelerate their expansion. Epimede actively supports its portfolio by taking board seats and participating in strategic decisions, offering operational and strategic guidance.
The firm's genesis stems from the insight that innovative SMEs require more than funding; they need hands-on strategic partnership. Epimede was established to integrate financial investment with deep operational expertise, leveraging its team's business development background. This collaborative model offers entrepreneurs guidance beyond capital.
Epimede serves ambitious entrepreneurs in technology sectors, assisting them in refining business strategy, product positioning, and market expansion. The company's vision is to proactively partner to transform innovative concepts into successful ventures, empowering its portfolio to achieve ambitious growth through development, financing, and internationalization.
Epimede has 1 tracked investment across 1 company. The latest tracked deal is $25.8M Series B Extension in Imcyse in February 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 17, 2021 | Imcyse | $25.8M Series B Extension | — | Biogenosis, KU Leuven, LSP, Noshaq, Pfizer, Sfpi Fpim, Sriw |